Board of Directors
Corporate and social responsibility
Small Molecule Therapeutics
The Endocannabinoid System
Overview & Timeline
Exxel Pharma is focused on
Commercialization of its FAAH inhibitor drugs and providing innovative medicines to current, unmet medical needs.
Positioning URB937 as a novel treatment for chronic cough and a safe, non-addictive alternative to opioid drugs for pain management.
Expanding the Company’s drug pipeline with follow-on molecules, and maximizing the value of the Company’s IP portfolio.
Achieving the goal of providing optimal returns for our investors.
Sign-up For Investor Updates
Enter your contact information